openPR Logo
Press release

Austrianova files Drug Master File with FDA

07-28-2020 12:54 PM CET | Health & Medicine

Press release from: Austrianova

Syringe containing Cell-in-a-Box encapsulated cells. The capsules are stained blue for visualisation.

Syringe containing Cell-in-a-Box encapsulated cells. The capsules are stained blue for visualisation.

S.E. Asian company, Austrianova, headquartered in Singapore, announced today that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). This DMF provides all confidential and detailed information covering the production of Cell-in-a-Box® encapsulated cell products based on encapsulated HEK293 cells and derivatives. This includes CypCaps™, the encapsulated cell product that its’ partner and client PharmaCyte Biotech Inc., is about to use in their late stage clinical trial for locally advanced, inoperable pancreatic cancer.

Austrianova’s CEO, Brian Salmons, said “The filing of this comprehensive DMF document is an important milestone event for Austrianova and represents a culmination of many years work on cell encapsulation based on this cell line. The DMF deposited with FDA describes confidential and detailed information about the facilities, processes, and materials used in the manufacturing, processing, packaging, and storing of Cell-in-a-Box® products based on HEK293 cells. The information contained in the DMF will be used to support PharmaCyte’s Investigational New Drug Application (IND) on CypCaps™ for the upcoming clinical trial for the treatment of pancreatic cancer.”

A DMF is a document that is submitted to a regulatory agency and contains complete information on an Active Pharmaceutical Ingredient and/or finished Drug Product. It comprises factual and complete information on a Drug Product's raw materials, process development and manufacture, analytical methods, stability, purity, packaging and its cGMP status. The DMF filing allows a company to protect its’ intellectual property from partners while complying with regulatory requirements for disclosure of processing details.

Austrianova, The Gemini, 41 Science Park Rd, Singapore 117610

Austrianova, (www.austrianova.com) part of the SG Austria Group, is a biotech company with a global footprint and headquarters in Singapore. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated human or animal cells from rejection by the immune system and allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop a wide range of standard cells as one-for-all living pharmaceuticals. Bac-in-a-Box® is a similar protective device adapted for encapsulation of bacteria and yeast, including probiotics, and has both human food as well as animal feed applications due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid. Austrianova now also offers GMP4Cells that includes competitively priced Master Cell Bank and Working Cell Bank production as well as “Fill and Finish” services for cell therapy products (such as stem cell therapies, biologics produced from cells e.g. vaccines, antibodies, recombinant proteins etc).

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Austrianova files Drug Master File with FDA here

News-ID: 2097898 • Views: 574

More Releases from Austrianova

Complete protection of probiotics from destruction by stomach acid using Bac-in- …
Austrianova announced today that a key publication on the ability of its patented technology, Bac-in-a-Box, to completely protect probiotics from acidic conditions found in the stomach has been published in the well respected journal “Microbial Cell Factories” https://rdcu.be/cbn0O. Stomach acid is nature’s way of ensuring that any microbes in food are killed before they reach the intestines. In the same way, stomach acid is also a formidable barrier to
Cells for Cells and Austrianova announce publication on novel method to produce …
Austrianova and Cells for Cells have just jointly published a ground breaking, peer reviewed, scientific publication on a novel, cost and time-saving method to generate extra-cellular vesicles (EVs) from encapsulated Mesenchymal Stem Cells (MSCs). These EVs are known to mediate many of the therapeutic effects of stem cells. The authors show that Austrianova's proprietary Cell-in-a-Box encapsulation technology can be used to produce and deliver EVs from encapsulated MSC's, as demonstrated using

More Releases for Cell

Single Cell Analysis Market
Single Cell Analysis Market Size Worth $ 4,752.19 Million By 2026 | CAGR: 18.4% The global Single Cell Analysis market size is expected to reach USD 4,752.19 million by 2026 according to a new study by WhipSmart MI Research. The report “Single Cell Analysis Market By Product (Consumables and Instruments), Cell Type (Human, Microbial and Animal), Technique (Flow Cytometers, Next-Generation Sequencing, Polymerase Chain Reaction, Microscopy, Mass Spectrometry and Other Techniques), Application
Fuel Cell Vehicle Market
The report aims to provide an overview of the global Fuel Cell Vehicle Market with detailed market segmentation by technology, vehicle type, and geography. The global fuel cell vehicle market is expected to witness high growth during the forecast period. The fuel cell vehicle market report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market. Get Sample Copy of
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports. This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions. This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer. Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u Top Key Players: - Becton, Dickinson and Company Biospherix EMD Millipore Eppendorf AG Merck KGaA Sartorius AG VWR International Cell culture is a rapidly emerging
Cell Therapy Market Cell Therapy Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Cell Therapy Necessity for Cell Therapy Treatment 2.1 Emergence of Stem Cell Research 2.2 Benefits of Using the Stem Cell for Research and Treatment Application of Stem Cells in Cell Therapy 3.1 Stem Cells Ability to Differentiate 3.1.1 Totipotent Stem Cells 3.1.2 Pluripotent Stem Cells 3.1.3 Multipotent
Cell Science 2017
It takes us immense pleasure to announce the conference that “Annual Congress on Cell Science, Stem Cell Research & Regenerative Medicine” which is going to be held during November 29-30, 2017 at Atlanta, USA. Cell Science 2017 conference will focus on the latest and exciting innovations in all areas of Cell Biologists and Stem Cell Researchers which offer a unique opportunity for investigators across the globe to meet, network, and perceive